Dose individualisation for carboplatin in cancer chemotherapy;Individualisation de dose du carboplatine en chimiotherapie

Bulletin du Cancer

Volumn 84, Issue 6, 1997, Pages 675-677

  Oudard, Stéphane ^a   Lauraine, Eric Pujade ^a  

^a HÔTEL DIEU   (France)

Author keywords

Calvert formula; Carboplatin; Chatelut formula; Dose adaptation

Indexed keywords

CARBOPLATIN;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG EFFICACY; HUMAN; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NEOPLASMS; THROMBOCYTOPENIA;

EID: 0030762438     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E. Results of a Southwest Oncology group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophasmide in advanced ovarian cancer. Oncology 1993 ; 50 : 2-9.
2. Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostopoulou F, Skarlos D. Cisplatin/étoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Sem Oncol 1994 ; 21 : 23-30.
3. Reed E, Ostchega Y, Steinberg SM, Yuspa SH, Young RC, Ozols RF, Poirier MC. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 1990 ; 50 : 2256-60.
4. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Bowall FE, et al. Carboplatin dosage: propective evaluation of a simple formula based on renal function. J Clin Oncol 1989 ; 7 : 1748-56.
5. Egorin MJ, Echo DAV, Tippings SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J. The pharmacokinetics of cis-diammine (1,1-cyclobutane dicarboxylato)platinum in patients with normal and impaired renal function. Cancer Res 1984 ; 44 : 5432-8.
6. Daugaard G, Rossing N, Rorth M. Effects of cisplatine on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988 ; 21 : 163-7.
7. Chatelut E, Canal P, Brunner V, Chereau C, Pujol A, Boneu A, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995 ; 87 : 573-80.
8. Horwich A, Dearnley DP, Nicholls J, Jay G, Mason M, Harland S, et al. Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good-pronostis metastatic germ cell tumours. J Clin Oncol 1991 ; 9 : 62-9.
9. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992 ; 10 : 520-8.
10. Lind MJ, Ghazal-Aswad S, Gumbrell L, Fishwick K, Craigs D, Millward AAJ, et al. Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer. J Clin Oncol 1996 ; 14 : 800-5.
11. Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, et al. Dose-effect study of carboplatin in ovarian cancer : a Danish ovarian cancer group study. J Clin Oncol 1997 ; 15 : 193-8.